Clinical Trials Logo

Clinical Trial Summary

To study qualitatively and quantitatively the Imaging Biomarkers (IBs) on Multi-modal Imaging with Novel technologies (MINT), in order to understand their role in prediction of the Age-related Macular Degeneration (AMD) progression in eyes with and without treatment. The understanding of IBs will allow early detection of AMD, prediction of its evolution, and guidance for the best options for stratified/individualized treatment of AMD.


Clinical Trial Description

The qualitative studies will explore use of OCT Angiography (OCTA), Swept Source OCT (SS-OCT), Ultra-Wide Field Fluorescein Angiography (UWF-FA), Adaptive Optic Scanning Laser Ophthalmoscopy (AO-SLO), Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO), Retro Mode Imaging (RMI) and other novel technologies for the retinal diagnosis. Morphologic qualitative IBs described in the literature like macular neovascularization pattern, retinal tubulations, choriocapillary preservation, retinal pigment epithelium atrophy, drusen patterns, etc as well as other IBPAMD original IBs classified in morphopathogenic categories like IBs related-to-MNV, IBs related-to-atrophy, IBs related-to macular chorio-retinal architecture, etc are analyzed in granular fashion by multi-modal imaging approach before and after different treatments for AMD.

The quantitative IBs assessment will be done in dual mode - classic and original to the IBPAMD trial. The lesions are quantitatively assessed on one hand, by using the classic measurements of the greatest diameter, total lesions area, vessels density, fractal dimension, etc, based on the classic concept of measurements expressed in absolute values (mm, mm2 or pixels). The same lesions are quantitatively assessed by using the original IBPAMD algorithm and software (SITE-app) that introduce a new concept in the quantification of the retinal lesions, the assessment of differences reported to the baseline. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04537143
Study type Observational
Source Doheny Image Reading Center
Contact
Status Withdrawn
Phase
Start date January 2021
Completion date January 2023

See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Recruiting NCT03893474 - Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners N/A
Completed NCT00971464 - Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation Phase 2
Terminated NCT00332657 - Anecortave Acetate Risk Reduction Trial (AART) Phase 3
Recruiting NCT04796545 - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration N/A
Completed NCT01766596 - Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort) N/A
Completed NCT03322930 - Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
Completed NCT01778491 - AMD Phenotype and Genotype Study
Completed NCT01016873 - INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD Phase 2
Active, not recruiting NCT03845582 - Phase 3 Study of ALK-001 in Geographic Atrophy Phase 3
Completed NCT03372746 - Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
Completed NCT03367767 - Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
Terminated NCT00333216 - Anecortave Acetate Risk-Reduction Trial (AART) Phase 3
Completed NCT01570790 - Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT00346866 - Anecortave Acetate Versus Placebo in AMD Patients Following PDT Phase 2
Withdrawn NCT00726466 - Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration Phase 1
Completed NCT00306488 - OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration Phase 2
Terminated NCT02348359 - X-82 to Treat Age-related Macular Degeneration Phase 2
Completed NCT01632527 - Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD) Phase 1/Phase 2
Withdrawn NCT01339949 - Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV) N/A